| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.065 | 0.08 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.059 | 0.09 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | 0.054 | 0.09 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.09 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.09 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.056 | 0.09 |